Company Overview and News

45
Sensex ends flat amid trade war fears, midcaps outperform; Nifty gains 2% for week

2018-04-06 moneycontrol
Benchmark indices ended rangebound session on a flat note Friday amid the trade standoff between world's largest economies US and China. Investors after digesting RBI policy await March quarter earnings that will start next week.
AMKD AJCON 500325 RELIANCE HCTHY 532418 AMTEKAUTO 532712 BHRQY 532215 500470 532187 RCOM AXISBANK RIGD 532480 532281 HDFCBANK BJJQY BHARTIARTL RLNIY 500034 UBNC AXB INDUSINDBK IBN ALBK 511692 AXBKY 532454 AXBA ICICIBANK BAJFINANCE TTST TATASTEEL TATLY HDB 532174 500180 HCLTECH 520077 ANDHRABANK

41
Easing trade war woes, lower inflation forecast by RBI lift Sensex 578 pts, Nifty above 10,300

2018-04-05 moneycontrol
Bulls took complete control over Dalal Street on Thursday as the Sensex surged more than 600 points intraday on easing trade war concerns and lower inflation forecast by RBI. Investors' wealth increased by Rs 2.6 lakh crore.
INDIANB AJCON 532814 532978 BHRQY 532215 505200 SYNDIBANK 500470 532483 AXISBANK BJJQY 500570 BHARTIARTL TATAMOTORS EICHERMOT 500034 YESBANK ECQRY UBNC AXB KMBKY IBN 511692 532648 YYBKY CNRYY AXBKY 532454 AXBA ICICIBANK BAJAJFINSV 532276 BAJFINANCE TTST TATASTEEL TATLY 532174 KOTAKBANK 500247 CANBK TTM

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...